Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
148,00 €
1,91 %
Neurocrine Biosciences (NBIX) had its price target raised by Canaccord Genuity Group Inc. from $164.00 to $200.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Citigroup Inc. from $204.00 to $242.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Leerink Partners from $160.00 to $170.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Wedbush from $166.00 to $176.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by Guggenheim. They now have a $175.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Piper Sandler from $190.00 to $207.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Royal Bank Of Canada from $176.00 to $180.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Citigroup Inc. from $242.00 to $246.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Truist Financial Corporation from $140.00 to $155.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by JPMorgan Chase & Co. from $177.00 to $185.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) is now covered by Sanford C. Bernstein. They set an "outperform" rating and a $221.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Royal Bank Of Canada from $180.00 to $183.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $213.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) was upgraded by Zacks Research from "hold" to "strong-buy".
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in Amazon.com Inc. diskutieren